Barclays’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-34,444
| Closed | -$515K | – | 5586 |
|
|
2022
Q4 | $515K | Buy |
34,444
+26,622
| +340% | +$369K | ﹤0.01% | 3296 |
|
|
2022
Q3 | $65K | Buy |
7,822
+2,044
| +35% | +$15.7K | ﹤0.01% | 3699 |
|
|
2022
Q2 | $38K | Sell |
5,778
-243
| -4% | -$1.18K | ﹤0.01% | 4151 |
|
|
2022
Q1 | $34K | Buy |
+6,021
| New | +$24.8K | ﹤0.01% | 4271 |
|
|
2019
Q3 | – | Sell |
-22,236
| Closed | -$165K | – | 7389 |
|
|
2019
Q2 | $150K | Buy |
22,236
+19,207
| +634% | +$165K | ﹤0.01% | 5364 |
|
|
2019
Q1 | $25K | Buy |
+3,029
| New | +$31.3K | ﹤0.01% | 6272 |
|
|
2018
Q4 | – | Sell |
-3,894
| Closed | -$85.7K | – | 7620 |
|
|
2018
Q3 | $129K | Buy |
3,894
+3,148
| +422% | +$80.9K | ﹤0.01% | 5349 |
|
|
2018
Q2 | $17K | Sell |
746
-28,004
| -97% | -$664K | ﹤0.01% | 6291 |
|
|
2018
Q1 | $834K | Sell |
28,750
-1,798
| -6% | -$52.6K | ﹤0.01% | 3428 |
|
|
2017
Q4 | $852K | Sell |
30,548
-1,442
| -5% | -$44.8K | ﹤0.01% | 3269 |
|
|
2017
Q3 | $1.17M | Buy |
+31,990
| New | +$989K | ﹤0.01% | 2858 |
|
|
2014
Q4 | – | Sell |
-5
| Closed | – | – | 7747 |
|
|
2014
Q3 | $0 | Sell |
5
-8,628
| -100% | -$110K | ﹤0.01% | 7914 |
|
|
2014
Q2 | $86K | Buy |
8,633
+8,413
| +3,824% | +$109K | ﹤0.01% | 5538 |
|
|
2014
Q1 | $2K | Buy |
220
+89
| +68% | +$1.6K | ﹤0.01% | 7423 |
|
|
2013
Q4 | $1K | Buy |
131
+79
| +152% | +$1.58K | ﹤0.01% | 7470 |
|
|
2013
Q3 | $1K | Sell |
52
-920
| -95% | -$21.1K | ﹤0.01% | 7330 |
|
|
2013
Q2 | $25K | Buy |
+972
| New | +$41.5K | ﹤0.01% | 6731 |
|
Barclays's AVEO Position: Q1 2023 in Review
Barclays sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 34,444 shares — an estimated $515K sold.
Barclays first reported a position in AVEO in Q2 2013 and held it in 17 quarters. The position peaked at $1.17M in Q3 2017. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Barclays reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Barclays sold 34,444 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $515K.
- Barclays first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 17 quarters.
- Barclays's AVEO Pharmaceuticals, Inc. position peaked at $1.17M in Q3 2017.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.